Business Wire

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, ...

BioInvent International: BioInvent to Present Clinical Data on FcyRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence in Relapsed/Refractory NHL at ...

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory ...
Medscape

Rituximab’s Role in Systemic Lupus Erythematosus Set for Further Randomized Controlled Trials

MANCHESTER, England — Two new randomized controlled trials (RCTs) assessing the role of rituximab in the treatment of various stages of systemic lupus erythematosus (SLE) have the green light to start ...
Renal & Urology News

Rituximab Effective for Relapsing or Steroid-Dependent Nephrotic Syndrome

In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...
TMCnet

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with ...